Aging-Related Circulating Particle-Associated Lipoprotein B Oxidase (apoBNOX) and Inhibitors Thereof
AssigneeNox Technologies, Inc.
InventorD. James Morré
Life of this patent
Estimating the term…
Loading patent…
AssigneeNox Technologies, Inc.
InventorD. James Morré
Estimating the term…
Provided is an age-related apolipoprotein B oxidase (apoBNOX) found tightly associated with the low-density lipoprotein particles and believed to be responsible for oxidizing lipoprotein particles and initiating atherogenesis. It causes damage by directly oxidizing the apolipoprotein B protein and indirectly oxidizing the lipids in the particles due to superoxide formation by the apoBNOX and its conversion into hydrogen peroxide. apoBNOX activity is inhibited by tyrosol and hydroxytyrosol and components of white wine, important components of French and Mediterranean diets, which seem to be a very good source of inhibitors of the apolipoprotein B oxidase. Agents comprising at least one naturally-occurring apoBNOX inhibitor and compositions lessen, ameliorate or treat disorders and complications resulting from cell damage caused by oxidation of apolipoprotein B. Also provided is an assay system comprising recombinant apoBNOX or an equivalent peptide and apolipoprotein B purified from human sera as a model to screen for agents and supplements that lower apoBNOX activity when administered orally.
A method of identifying an inhibitor of apolipoprotein B NADH oxidase (apoBNOX), said method comprising the steps of
A composition useful for reducing the effects of apolipoprotein B NADH oxidase (apoBNOX) on lipoprotein oxidation comprising an effective amount of at least one apoBNOX inhibitory agent, or natural source wherein the apoBNOX inhibitory agent is effective in decreasing the effects of apoBNOX on lipoprotein B oxidation.
A kit useful for reducing or delaying or treating the effects of apoBNOX on apoprotein B oxidation comprising a composition comprising at least one apoBNOX inhibitory agent and instructions for use.
The use of an apoBNOX inhibitor in the formulation of a medicament or nutritional supplement to reduce risk of cardiovascular disease.
Dependencies are inferred from the claim text.